Literature DB >> 14966563

Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.

Martin O Bergo1, Bryant J Gavino, Christine Hong, Anne P Beigneux, Martin McMahon, Patrick J Casey, Stephen G Young.   

Abstract

Isoprenylcysteine carboxyl methyltransferase (Icmt) methylates the carboxyl-terminal isoprenylcysteine of CAAX proteins (e.g., Ras and Rho proteins). In the case of the Ras proteins, carboxyl methylation is important for targeting of the proteins to the plasma membrane. We hypothesized that a knockout of Icmt would reduce the ability of cells to be transformed by K-Ras. Fibroblasts harboring a floxed Icmt allele and expressing activated K-Ras (K-Ras-Icmt(flx/flx)) were treated with Cre-adenovirus, producing K-Ras-Icmt(Delta/Delta) fibroblasts. Inactivation of Icmt inhibited cell growth and K-Ras-induced oncogenic transformation, both in soft agar assays and in a nude mice model. The inactivation of Icmt did not affect growth factor-stimulated phosphorylation of Erk1/2 or Akt1. However, levels of RhoA were greatly reduced as a consequence of accelerated protein turnover. In addition, there was a large Ras/Erk1/2-dependent increase in p21(Cip1), which was probably a consequence of the reduced levels of RhoA. Deletion of p21(Cip1) restored the ability of K-Ras-Icmt(Delta/Delta) fibroblasts to grow in soft agar. The effect of inactivating Icmt was not limited to the inhibition of K-Ras-induced transformation: inactivation of Icmt blocked transformation by an oncogenic form of B-Raf (V599E). These studies identify Icmt as a potential target for reducing the growth of K-Ras- and B-Raf-induced malignancies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966563      PMCID: PMC338259          DOI: 10.1172/JCI18829

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

Authors:  H R Ashar; L James; K Gray; D Carr; M McGuirk; E Maxwell; S Black; L Armstrong; R J Doll; A G Taveras; W R Bishop; P Kirschmeier
Journal:  Exp Cell Res       Date:  2001-01-01       Impact factor: 3.905

2.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

3.  Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.

Authors:  C A Omer; Z Chen; R E Diehl; M W Conner; H Y Chen; M E Trumbauer; S Gopal-Truter; G Seeburger; H Bhimnathwala; M T Abrams; J P Davide; M S Ellis; J B Gibbs; I Greenberg; K S Koblan; A M Kral; D Liu; R B Lobell; P J Miller; S D Mosser; T J O'Neill; E Rands; M D Schaber; E T Senderak; A Oliff; N E Kohl
Journal:  Cancer Res       Date:  2000-05-15       Impact factor: 12.701

4.  Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells.

Authors:  M O Bergo; G K Leung; P Ambroziak; J C Otto; P J Casey; S G Young
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

5.  Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation.

Authors:  Martin O Bergo; Patricia Ambroziak; Cria Gregory; Amanda George; James C Otto; Edward Kim; Hiroki Nagase; Patrick J Casey; Allan Balmain; Stephen G Young
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

Review 6.  Farnesyltransferase inhibitors: potential role in the treatment of cancer.

Authors:  A D Cox
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Ras and Rho regulation of the cell cycle and oncogenesis.

Authors:  K Pruitt; C J Der
Journal:  Cancer Lett       Date:  2001-09-28       Impact factor: 8.679

Review 8.  Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.

Authors:  S M Sebti; A D Hamilton
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

9.  Isoprenylcysteine carboxyl methyltransferase deficiency in mice.

Authors:  M O Bergo; G K Leung; P Ambroziak; J C Otto; P J Casey; A Q Gomes; M C Seabra; S G Young
Journal:  J Biol Chem       Date:  2000-12-19       Impact factor: 5.157

10.  Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility.

Authors:  E Sahai; M F Olson; C J Marshall
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

View more
  70 in total

1.  Amide-modified prenylcysteine based Icmt inhibitors: Structure-activity relationships, kinetic analysis and cellular characterization.

Authors:  Jaimeen D Majmudar; Heather B Hodges-Loaiza; Kalub Hahne; James L Donelson; Jiao Song; Liza Shrestha; Marietta L Harrison; Christine A Hrycyna; Richard A Gibbs
Journal:  Bioorg Med Chem       Date:  2011-11-06       Impact factor: 3.641

2.  Fighting cancer by disrupting C-terminal methylation of signaling proteins.

Authors:  Steven Clarke; Fuyuhiko Tamanoi
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

3.  S-Farnesyl-Thiopropionic Acid (FTPA) Triazoles as Potent Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase.

Authors:  Joel A Bergman; Kalub Hahne; Jiao Song; Christine A Hrycyna; Richard A Gibbs
Journal:  ACS Med Chem Lett       Date:  2011-11-28       Impact factor: 4.345

4.  Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism.

Authors:  J T Teh; W L Zhu; O R Ilkayeva; Y Li; J Gooding; P J Casey; S A Summers; C B Newgard; M Wang
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

5.  Effects of isoprenylcysteine carboxyl methyltransferase silencing on the proliferation and apoptosis of tongue squamous cell carcinoma.

Authors:  Shao-Ru Wang; Wei Sun; Nan Zhou; Kai Zhao; Wen-Jian Li; Zeng-Peng Chi; Ying Wang; Qi-Min Wang; Lei Tong; Zong-Xuan He; Hong-Yu Han; Zheng-Gang Chen
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-02-01

Review 6.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

7.  Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases.

Authors:  David Michaelson; Wasif Ali; Vi K Chiu; Martin Bergo; Joseph Silletti; Latasha Wright; Stephen G Young; Mark Philips
Journal:  Mol Biol Cell       Date:  2005-01-19       Impact factor: 4.138

8.  Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

Authors:  Helen Court; Marc Amoyel; Michael Hackman; Kyoung Eun Lee; Ruliang Xu; George Miller; Dafna Bar-Sagi; Erika A Bach; Martin O Bergö; Mark R Philips
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.

Authors:  Anna-Karin M Sjogren; Karin M E Andersson; Meng Liu; Briony A Cutts; Christin Karlsson; Annika M Wahlstrom; Martin Dalin; Carolyn Weinbaum; Patrick J Casey; Andrej Tarkowski; Birgitta Swolin; Stephen G Young; Martin O Bergo
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.